Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables
Abstract
Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients.
This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables.
The study uses the public ACRIN 6698/I-SPY2 multicenter dataset.
The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information.
Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter.
Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model.
Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74.
Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively.
The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86.
These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.